Almost fifty years after its first introduction into clinical care, clozapine remains the only
evidence-based pharmacological option for treatment-resistant schizophrenia (TRS), which …

Antipsychotics represent the mainstay of schizophrenia pharmacological therapy, and their
role has been expanded in the last years to mood disorders treatment. Although introduced …

The mortality rate of patients with schizophrenia is high, and life expectancy is shorter by 10
to 20 years. Metabolic abnormalities including type 2 diabetes mellitus (T2DM) are among …

Synapses are implicated in many neuropsychiatric illnesses. Here, we provide an overview
of in vivo techniques to index synaptic markers in patients. Several positron emission …

Emerging evidence from genomics, post-mortem, and preclinical studies point to a potential
dysregulation of molecular signaling at postsynaptic density (PSD) in schizophrenia …

Schizophrenia is a severe psychiatric illness affecting almost 25 million people worldwide
and is conceptualized as a disorder of synaptic plasticity and brain connectivity …

Schizophrenia is a severe mental illness characterized by alterations in processes that
regulate both synaptic plasticity and functional connectivity between brain regions …

Introduction Treatment resistant schizophrenia (TRS), the lack of response to at least two
antipsychotics administered at adequate dose and duration, epitomizes in psychiatry one of …

The current literature globally highlights the efficacy of Clozapine in several psychiatric
disorders all over the world, with an FDA indication for reducing the risk of repeated suicidal …

Schizophrenia is a chronic disease presented with psychotic symptoms, negative symptoms,
impairment in the reward system, and widespread neurocognitive deterioration. Disruption …